Printer Friendly

MALCOLM MORVILLE, PH.D., JOINS PLANT PHARMACEUTICALS, INC. AS PRESIDENT AND CEO; GUSTAV CHRISTENSEN NAMED CHAIRMAN OF THE BOARD

 WORCESTER, Mass., March 25 /PRNewswire/ -- Plant Pharmaceuticals, Inc. announced today the appointment of Malcolm Morville, Ph.D., as president and CEO. Gustav Christensen has been named chairman of the board.
 Plant Pharmaceuticals is a recently established biotechnology company that is applying novel, world-class capabilities in plant tissue culture to the discovery and development of plant-derived compounds to treat major human diseases.
 "Malcolm Morville brings to Plant Pharmaceuticals 23 years of business and research management experience from Pfizer Inc. and ImmuLogic Pharmaceutical Corporation," said Robert G. Foster, president and CEO of Commonwealth BioVentures. "Gustav Christensen has an outstanding record in management and business development in biotechnology and healthcare at leading companies, including Alpha-Beta Technology, Baxter Healthcare, Genetics Institute and ImmuLogic. We are pleased they have joined our effort to discover and develop plant-derived pharmaceuticals."
 "We believe that our established expertise in plant tissue culture and biotechnology will enable us to capitalize on the drug discovery opportunities presented by the enormous diversity of plant species," added Morville. "Although plants are currently an important source of pharmaceutical products, the potential therapeutic value of plant- derived compounds remains largely untapped."
 The company was founded in May 1992 by Commonwealth BioVentures Inc., together with Alexander Klibanov, Ph.D. and Robert Langer, Ph.D., both professors at M.I.T., and Professor Michael Fowler, University of Sheffield (England). Prior to the appointment of Morville, Foster served as Acting President of Plant Pharmaceuticals.
 Morville joins Plant Pharmaceuticals from ImmuLogic, where since 1988 he served in a variety of senior management positions, most recently as Division Vice President, Allergic Diseases Strategic Business Unit. In the 17 years prior to ImmuLogic, he held various scientific and management positions at Pfizer, Inc. His most recent position at Pfizer was as Director, Department of Immunology and Infectious Diseases at Pfizer Central Research. Morville received his Ph.D. in Biochemistry at the University of Manchester Institute of Science and Technology (England).
 Christensen is currently chairman of the board at Alpha-Beta Technology, Inc. and a partner in Commonwealth BioVentures. He will continue his responsibilities in both of those positions. Christensen was formerly president and CEO of ImmuLogic Pharmaceutical Corporation. Previously, he served as senior vice president, Commercial Affairs at Genetics Institute. Prior to Genetics Institute, he held various management positions at Baxter International. Christensen received his M.Sc. in Economics from the University of Aarhus (Denmark), and an M.B.A. from Harvard Business School.
 Plant Pharmaceuticals is based in Worcester, Mass., and maintains a plant cell biotechnology operation, Plant Sciences Limited, at the University of Sheffield, England. The company acquired Plant Sciences in September 1992. Major investors in the company include Commonwealth BioVentures IV Limited Partnership; Dillon, Read Venture Capital; and BancBoston Ventures, Inc.
 -0- 3/25/93
 /CONTACT: Malcolm Morville, Ph.D., Plant Pharmaceuticals, Inc., 508-793-1565/


CO: Plant Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER

DJ -- NE002 -- 9396 03/25/93 08:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 25, 1993
Words:484
Previous Article:JACOBS ENGINEERING/HUMPHREYS & GLASGOW RECEIVE $22.5 MILLION THAMES WATER AWARD
Next Article:LEGENDARY JIM SHOOTER DEFIANTLY CREATES NEW CONCEPT IN TRADING CARDS; COMICS COMPANY DEFIANT CREATES CARD SET THAT IS ACTUALLY A COMIC BOOK
Topics:


Related Articles
ERICKSON NAMED CEO OF TELIOS PHARMACEUTICALS
PHYTERA SIGNS RESEARCH AND MARKETING AGREEMENT WITH TSUMURA
Phytera, Inc. Acquires Auda Pharmaceuticals, ApS, a Danish Combinatorial Chemistry Company
Pharmadigm Names Max Link, Ph.D., to Chairman of the Board
Phytera and NeuroSearch Sign Research, Development and Marketing Agreement
Demegen Appoints Jerry B. Hook to the Board of Directors.
William Claypool Joins Morphotek Board of Directors.
BIOCOM Announces New Board Members.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters